Table 29Summary strength of evidence for KQ 3: Mean pulmonary artery pressure

ComparisonNumber of Studies (Patients)DomainsStrength of Evidence
Effect Estimate (95% CI)
Risk of BiasConsistencyDirectnessPrecision
Endothelin antagonists vs. placebo6 (219)Low (4)
Moderate (2)
ConsistentIndirectPreciseSOE = Low
Mean difference −3.5
(−6.5 to −0.5)
Favors endothelin antagonists
Phosphodiesterase inhibitors vs. placebo2 (481)Low (1)
Moderate (1)
ConsistentIndirectPreciseSOE = Low
Mean difference −3.6
(−5.2 to −2.0)
Favors PDE inhibitors
Prostanoids vs. placebo or standard therapy5 (859)Low (4)
Moderate (1)
ConsistentIndirectPreciseSOE = Low
Mean difference −3.2
(−5.6 to −0.8)
Favors prostanoids
Combination therapy vs. monotherapy2 (90)Low (2)InconsistentIndirectPreciseSOE = Low
Mean difference −4.1
(−7.6 to −0.6)
Favors combination therapy

CI=confidence interval; OR=odds ratio; SOE=strength of evidence

From: Results

Cover of Pulmonary Arterial Hypertension: Screening, Management, and Treatment
Pulmonary Arterial Hypertension: Screening, Management, and Treatment [Internet].
Comparative Effectiveness Reviews, No. 117.
McCrory DC, Coeytaux RR, Schmit KM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.